早期关节炎治愈诱导(I CEA):一项研究者发起的随机单盲临床试验方案,含开放标签扩展,比较新诊断未分化关节炎患者的三种治疗策略
I CEA试验为多中心单盲随机对照研究,纳入症状持续时间小于1年的未分化关节炎患者,按1:1:1随机分为症状缓解组、甲氨蝶呤组和巴瑞替尼组,主要结局为3个月时DAS变化。研究计划12个月,实际纳入人数低于初始计划并更新了样本量计算。
要点
- 未分化关节炎可能自行缓解,也可能进展为类风湿关节炎等,早期使用改善病情抗风湿药获益证据有限。
- I CEA试验比较症状缓解、甲氨蝶呤和巴瑞替尼三种起始策略,主要结局为3个月时DAS变化。
- 巴瑞替尼安全性警告促使方案调整,排除标准更严格,实际纳入人数低于初始计划。
核心结论
- I CEA试验旨在评估未分化关节炎患者早期使用甲氨蝶呤或巴瑞替尼是否优于等待自行缓解的症状治疗。
- 研究实际纳入人数低于初始计划,并依据更新的样本量计算进行了调整。
研究设计与样本
- 多中心、单盲(独立评估者)、随机、开放标签扩展临床试验,含3个月干预期和9个月观察随访期。
- 纳入症状持续时间小于1年、未使用过改善病情抗风湿药的未分化关节炎患者。
- 排除巴瑞替尼不良事件风险增加的患者。
- 按1:1:1随机分为三组:症状缓解组(非甾体抗炎药加单次糖皮质激素注射)、甲氨蝶呤组(加单次糖皮质激素注射,非甾体抗炎药可选)、巴瑞替尼组(加单次糖皮质激素注射,非甾体抗炎药可选)。
- 观察随访期间,患者与风湿科医生共同决策治疗。
主要发现
- 主要结局为3个月时DAS变化。
- 次要结局包括影像学进展、躯体功能、患者报告结局、成本效用、安全性、进展为可分类类风湿关节炎及随时间变化的疾病活动度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 实际纳入患者数低于初始计划,并依据更新的样本量计算进行了调整。
- 巴瑞替尼新出现的安全性警告促使方案调整,包括更广泛的排除标准。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Undifferentiated arthritis (UA) is a term used to describe patients with inflammatory arthritis that has not differentiated into a specific rheumatic disease. UA may be a pre-stage of rheumatoid arthritis (RA) or another inflammatory disease or remain undifferentiated, but a substantial proportion of patients may also achieve spontaneous remission. As UA may be an early presentation of RA, rheumatologists often start methotrexate (or another csDMARD) as early as possible. There are however very little data on the potential benefits of early DMARD treatment, and longitudinal data suggests that long-term outcomes such as physical functioning hardly improved in these patients in the past decades. In the I CEA trial, we investigate if it is beneficial to start early treatment with MTX or baricitinib, a more rapidly acting drug with a broader mechanism of action, compared to waiting for spontaneous remission with symptomatic therapy in patients with UA. METHODS: The I CEA is a multicenter single-blind (independent assessor) randomized clinical trial with a 3-month interventional and 9-month observational follow-up period. The study includes patients with early (< 1 year symptom duration) DMARD-naïve undifferentiated arthritis. Patients with an increased risk of AEs with baricitinib treatment are excluded. Participants are randomized 1:1:1 to (1) symptom relief with NSAIDs and a single injection of glucocorticoids and (waiting for spontaneous remission); (2) methotrexate and a single injection of glucocorticoids, and NSAIDs are optional; and (3) baricitinib and a single injection of glucocorticoids and NSAIDs are optional. During the observational follow-up period, patients are treated in shared decision with their rheumatologist. The primary outcome will be the change in DAS at 3 months. Secondary outcomes include radiographic progression, physical functioning, patient-reported outcomes, cost utilities, safety, progression to classifiable RA, and disease activity over time. DISCUSSION: The 12-month I CEA trial studies early treatment of patients with UA with methotrexate, baricitinib, or NSAIDs. The study initially had a more complex design. Emerging safety warnings about baricitinib necessitated adjustment of the trial protocol including more extensive exclusion criteria. The number of included patients was lower than initially planned, supported by an updated sample size calculation. TRIAL REGISTRATION: Dutch trial register NL73202.058.20, EudraCT 2019-004359-35, registered 10-06-2020. Protocol version 1Q, 06-05-2024.
引用
- Bergstra SA, van Ouwerkerk L, Nevins IS, et al. Induction of Cure in Early Arthritis (I CEA): study protocol for an investigator-initiated randomized single-blind clinical trial with open-label extension to compare three treatment strategies in patients with newly diagnosed undifferentiated arthritis. Trials. 2024. PMID: 39533416. doi:10.1186/s13063-024-08609-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。